Budgetary impact of new label indications after initial drug registration in Brazil: A case study of pembrolizumab and trastuzumab deruxtecan
The pharmaceutical landscape has undergone a transformative shift due to emerging technologies, leading to a projected value of USD 405.52 billion for the global pharmaceutical manufacturing market in 2020. Brazil, representing 2% of the global pharmaceutical market, boasts a comprehensive public health system called Sistema Único de Saúde (SUS), ensuring universal health coverage. However, the public and private health sectors in Brazil operate independently, with 23% of Brazilians possessing private health insurance plans. Regulated by the Brazilian Drug Market Regulation Chamber (CMED), which controls drug prices based on international retail prices and other factors, the pharmaceutical market in Brazil faces significant challenges in maintaining the sustainability of the Brazilian health-care system, particularly due to the high costs of cancer medications, such as pembrolizumab and trastuzumab deruxtecan. This study aims to assess the budgetary impact of expanding indications for pembrolizumab and trastuzumab deruxtecan in Brazil after their initial registration by the Brazilian Health Regulatory Agency. Utilizing epidemiological data from the National Cancer Institute (INCA) and clinical trial data, we estimated the eligible patient populations and associated costs for these medications. Trastuzumab deruxtecan’s eligible patient population increased from 383 to 23,000 across various indications, resulting in a total cost increase from USD 90.6 million to USD 5.0 billion. Similarly, pembrolizumab’s eligible patient population expanded from 1796 to 99,544 for multiple indications, causing the total cost increase from USD 121.1 million to USD 6.7 billion. The study highlights the substantial expansions in indications and patient eligibility for trastuzumab deruxtecan and pembrolizumab in Brazil, with significant budgetary implications potentially jeopardizing the health-care system’s sustainability. To ensure the long-term sustainability of health-care systems and to provide equitable access to optimal treatments, it is crucial for policymakers to monitor and adjust drug prices following their initial registration. Policymakers must be aware of these challenges and consider them in health-care policy development and decision-making processes.
Bach, P.B., & Saltz, L.B. (2017). Raising the dose and raising the cost: The case of Pembrolizumab in lung cancer. JNCI: Journal of the National Cancer Institute, 109:djx125. https://doi.org/10.1093/jnci/djx125
Brewer, G.J. (2006). Article commentary: Fundamental problems lie ahead in the drug discovery and commercialization process: Restructuring of the pharmaceutical industry and an improved partnership with academia are required. Journal of Investigative Medicine, 54(6):291-302. https://doi.org/10.2310/6650.2006.05030
CMED. (2004). Resolução CMED No 2, De 5 De Março De 2004-Português (Brasil). Available from: https://www. gov.br/anvisa/pt-br/assuntos/medicamentos/cmed/ air/arquivos/5517json-file-1/view [Last accessed on 2023 Jan 20].
Columbia University Mailman School of Public Health. (2020). Brazil Summary. Columbia University Mailman School of Public Health. Available from: https://www.publichealth. columbia.edu/research/others/comparative-health-policy-library/brazil-summary [Last accessed on 2023 Nov 07].
Cruz, J.A.W., da Cunha, M.A.V.C., de Moraes, T.P., Marques, S., Tuon, F.F., Gomide, A.L., et al. (2022). Brazilian private health system: History, scenarios, and trends. BMC Health Services Research, 22:49. https://doi.org/10.1186/s12913-021-07376-2
Da Veiga, C.R.P., da Veiga, C.P., & Drummond-Lage, A.P. (2018). Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies. Critical Reviews in Oncology/ Hematology, 129:133-145. https://doi.org/10.1016/j.critrevonc.2018.07.002
Daiichi Sankyo. (2023). ENHERTU® (Fam-trastuzumab Deruxtecan-nxki) Official Patient Website. Available from: https://www.enhertu.com [Last accessed on 2023 Jan 01].
De Farias, M., & Pinto, M.F.T. (2021). Criteria for setting drug prices in Brazil and selected countries: a comparative review. Brazilian Journal of Health Economics, 13(3):322-337. https://doi.org/10.21115/JBES.v13.n3.p322-37
Destiny Clinical Trials. (2023). DESTINY Clinical Trials for Metastatic Breast Cancer. Available from: https:// destinyclinicaltrials.com/en [Last accessed on 2023 Jan 01].
Dos Santos Dias, L.L., dos Santos, M.A.B., & Pinto, C.D.B.S. (2019). Contemporary regulation of drug prices in Brazil - a critical analysis. Saúde Em Debate, 43(121):543-558. https://doi.org/10.1590/0103-1104201912120
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5):E359-E386. https://doi.org/10.1002/ijc.29210
Franken, M., Heintz, E., Gerber-Grote, A., & Raftery, J. (2016). Health economics as rhetoric: The limited impact of health economics on funding decisions in four European countries. Value in Health, 19(8):951-956. https://doi.org/10.1016/j.jval.2016.08.001
Gammie, T., Lu, C.Y., & Babar, Z.U.D. (2015). Access to orphan drugs: A comprehensive review of legislations, regulations and policies in 35 countries. PLoS One, 10(10):e0140002. https://doi.org/10.1371/journal.pone.0140002
Goldstein, D.A., Stemmer, S.M., & Gordon, N. (2016). The cost and value of cancer drugs-are new innovations outpacing our ability to pay? Israel Journal of Health Policy Research, 5(1):40. https://doi.org/10.1186/s13584-016-0097-0
Grand View Research. (2023). Pharmaceutical Manufacturing Market Size Report, 2021-2028. Available from: https://www. grandviewresearch.com/industry-analysis/pharmaceutical-manufacturing-market [Last accessed on 2023 Apr 27].
Howard, D.H., Bach, P.B., Berndt, E.R., & Conti, R.M. (2015). Pricing in the market for anticancer drugs. Journal of Economic Perspectives, 29(1):139-162. https://doi.org/10.1257/jep.29.1.139
INCA. (2022). INCA Estima 704 Mil Casos de Câncer Por Ano no Brasil Até 2025. Instituto Nacional de Câncer-INCA. Available from: https://www.gov.br/inca/pt-br/assuntos/ noticias/2022/inca-estima-704-mil-casos-de-cancer-por-ano-no-brasil-ate-2025 [Last accessed on 2023 Apr 25].
Ivama-Brummell, A.M., Pingret-Kipman, D., Louly, P.G., & Andrade, R.R. (2022). Medicines regulation, pricing and reimbursement in Brazil. Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde, 13(1):769. https://doi.org/10.30968/rbfhss.2022.131.0769
Keam, S.J. (2020). Trastuzumab deruxtecan: First approval. Drugs, 80(5):501-508. https://doi.org/10.1007/s40265-020-01281-4
Kerr, S., Jazieh, A.R., & Kerr, D. (2017). How useful are international treatment guidelines in low-and middle-income countries? Journal of Global Oncology, 3(5):441-443. https://doi.org/10.1200/JGO.2016.008250
Keytruda HCP. (2023). Selected Indications for KEYTRUDA® (Pembrolizumab). Available from: https://www. keytrudahcp.com/approved-indications [Last accessed on 2023 Jan 20].
Marabelle, A., Le, D.T., Ascierto, P.A., Di Giacomo, A.M., De Jesus-Acosta, A., Delord, J.P., et al. (2020). Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology, 38(1):1-10. https://doi.org/10.1200/JCO.19.02105
Ministério da Saúde. (2023). Sistema de Informações Sobre Orçamentos Públicos em Saúde-SIOPS. Ministério da Saúde. Available from: https://www.gov.br/saude/pt-br/ acesso-a-informacao/siops/sistema-de-informacoes-sobre-orcamentos-publicos-em-saude-siops [Last accessed on 2023 Jul 11].
Modi, S., Saura, C., Yamashita, T., Park, Y.H., Kim, S.B., Tamura, K., et al. (2020). Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. TheNew England Journal of Medicine, 382(7):610-621. https://doi.org/10.1056/NEJMoa1914510
MSD. (2023). KEYTRUDA® (Pembrolizumab). Available from: https://www.keytruda.com [Last accessed on 2023 Jan 20].
OECD. (2023). Exchange Rates (Indicator). Doi: 10.1787/037ed317-en Available from: https://data.oecd. org/conversion/exchange-rates.htm [Last accessed on 2023 Feb 02].
Sharma, A., Jacob, A., Tandon, M., & Kumar, D. (2010). Orphan drug: Development trends and strategies. Journal of Pharmacy and Bioallied Sciences, 2(4):290-299. https://doi.org/10.4103/0975-7406.72128
Sleijfer`, S., & Verweij, J. (2016). Health policy: Affordability of drugs used in oncology health care. Natural Reviews, Clinical Oncology, 13(6):331-332. https://doi.org/10.1038/nrclinonc.2016.77
Tartari, F., Santoni, M., Burattini, L., Mazzanti, P., Onofri, A., & Berardi, R. (2016). Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. Cancer Treatment Reviews, 48:20-24. https://doi.org/10.1016/j.ctrv.2016.06.002
The Lowdown. (2021). Billions are Spent by the NHS on Drugs Every Year, but how does it Work? The Lowdown. Available from: https://lowdownnhs.info/drugs/billions-are-spent-by-the-nhs-on-drugs-every-year-but-how-does-it-work [Last accessed on 2023 Apr 25].
Viscusi, W.K., Harrington, J.E., & Vernon, J.M. (2005). Economics of Regulation and Antitrust. 4th ed. Cambridge, Mass: MIT Press.
Yu, P.P. (2016). Challenges in measuring cost and value in oncology: Making it personal. Value in Health, 19(5):520-524. https://doi.org/10.1016/j.jval.2016.04.017